Merus Labs International (MSLI) Earning Somewhat Favorable Media Coverage, Analysis Shows
News articles about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merus Labs International earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.5523079209815 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, Canaccord Genuity lowered shares of Merus Labs International to a “hold” rating and set a $1.65 price target on the stock. in a research report on Thursday, May 11th. Seven research analysts have rated the stock with a hold rating, The stock has a consensus rating of “Hold” and a consensus price target of $1.35.
Shares of Merus Labs International (NASDAQ:MSLI) remained flat at $1.30 during trading on Friday. The company had a trading volume of 9,409 shares. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $0.94. Merus Labs International has a 52 week low of $0.70 and a 52 week high of $1.33.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.